keyword
MENU ▼
Read by QxMD icon Read
search

Venlafaxine

keyword
https://www.readbyqxmd.com/read/27871747/impact-of-external-carbon-dose-on-the-removal-of-micropollutants-using-methanol-and-ethanol-in-post-denitrifying-moving-bed-biofilm-reactors
#1
Elena Torresi, Mònica Escolà Casas, Fabio Polesel, Benedek G Plósz, Magnus Christensson, Kai Bester
Addition of external carbon sources to post-denitrification systems is frequently used in wastewater treatment plants to enhance nitrate removal. However, little is known about the fate of micropollutants in post-denitrification systems and the influence of external carbon dosing on their removal. In this study, we assessed the effects of two different types and availability of commonly used carbon sources -methanol and ethanol- on the removal of micropollutants in biofilm systems. Two laboratory-scale moving bed biofilm reactors (MBBRs), containing AnoxKaldnes K1 carriers with acclimated biofilm from full-scale systems, were operated in continuous-flow using wastewater dosed with methanol and ethanol, respectively...
October 26, 2016: Water Research
https://www.readbyqxmd.com/read/27866243/monitoring-of-adherence-to-headache-treatments-by-means-of-hair-analysis
#2
Anna Ferrari, Manuela Licata, Cecilia Rustichelli, Carlo Baraldi, Daniele Vandelli, Filippo Marchesi, Federica Palazzoli, Patrizia Verri, Enrico Silingardi
PURPOSE: The aim of this study was to evaluate the potential of hair analysis to monitor medication adherence in headache patients undergoing chronic therapy. For this purpose, the following parameters were analyzed: the detection rate of 23 therapeutic drugs in headache patients' hair, the degree of agreement between the self-reported drug and the drug found in hair, and whether the levels found in hair reflected the drug intake reported by the patients. METHODS: The study included 93 patients suffering from primary headaches declaring their daily intake of at least one of the following drugs during the 3 months before the hair sampling: alprazolam, amitriptyline, citalopram, clomipramine, clonazepam, delorazepam, diazepam, duloxetine, fluoxetine, flurazepam, levomepromazine, levosulpiride, lorazepam, lormetazepam, mirtazapine, paroxetine, quetiapine, sertraline, topiramate, trazodone, triazolam, venlafaxine, and zolpidem...
November 20, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27842767/drug-hepatotoxicity-newer-agents
#3
REVIEW
Chalermrat Bunchorntavakul, K Rajender Reddy
Idiosyncratic hepatotoxicity is one of the most common reasons for an approved drug being restricted. This article focuses on hepatotoxicity of selected and recently introduced agents, such as, tyrosine kinase inhibitors, monoclonal antibodies, novel oral anticoagulants, newer antiplatelets, antibiotics, anti-diabetics, anti-epileptics, anti-depressants, anti-psychotics and anti-retrovirals. Overall, the incidence of clinically relevant hepatotoxicity from newer agents seems to be lower than that of the older agents...
February 2017: Clinics in Liver Disease
https://www.readbyqxmd.com/read/27837032/treatment-of-neuropathic-pain-with-venlafaxine-a-systematic-review
#4
REVIEW
Rohit Aiyer, Robert L Barkin, Anurag Bhatia
OBJECTIVE : To investigate the efficacy of venlafaxine for neuropathic pain and review literature to determine if the medication provides adequate neuropathic pain relief. METHODS : Literature was reviewed on MEDLINE using various key words. These key words include: "venlafaxine and pain," "venlafaxine ER and pain," "venlafaxine XR and pain," "venlafaxine and neuropathic pain," "venlafaxine and neuropathy," "SSRI and neuropathic pain," "SSRI and neuropathy," "SNRI and neuropathic pain," "SNRI and neuropathy," "serotonin reuptake inhibitor and neuropathic pain," "serotonin reuptake inhibitor and neuropathy," "serotonin norepinephrine reuptake inhibitor and neuropathic pain" and "serotonin norepinephrine reuptake inhibitor and neuropathy...
November 11, 2016: Pain Medicine: the Official Journal of the American Academy of Pain Medicine
https://www.readbyqxmd.com/read/27825327/treatment-of-trauma-affected-refugees-with-venlafaxine-versus-sertraline-combined-with-psychotherapy-a-randomised-study
#5
Charlotte Sonne, Jessica Carlsson, Per Bech, Ask Elklit, Erik Lykke Mortensen
BACKGROUND: The prevalence of trauma-related psychiatric disorders is high among refugees. Despite this, little is known about the effect of pharmacological treatment for this patient group. The objective of the present study was therefore to examine differences in the effects of venlafaxine and sertraline on Post-Traumatic Stress Disorder (PTSD), depression and functional impairment in trauma-affected refugees. METHODS: The study was a randomised pragmatic trial comparing venlafaxine and sertraline in combination with psychotherapy and social counselling...
November 8, 2016: BMC Psychiatry
https://www.readbyqxmd.com/read/27822048/analysis-of-treatment-patterns-and-persistence-on-branded-and-generic-medications-in-major-depressive-disorder-using-retrospective-claims-data
#6
Caitlyn T Solem, Ahmed Shelbaya, Yin Wan, Chinmay G Deshpande, Jose Alvir, Elizabeth Pappadopulos
BACKGROUND: In major depressive disorder (MDD), treatment persistence is critical to optimize symptom remission, functional recovery, and health care costs. Desvenlafaxine tends to have fewer drug interactions and better tolerability than other MDD drugs; however, its use has not been assessed in the real world. OBJECTIVE: The aim of the present study is to compare medication persistence and concomitant MDD drug use with branded desvenlafaxine (Pristiq(®)) compared with antidepressant drug groups classified as 1) branded selective serotonin reuptake inhibitors (SSRIs; ie, escitalopram [Lexapro™]) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs; ie, venlafaxine [Effexor(®)], duloxetine [Cymbalta(®)]) and 2) generic SSRIs/SNRIs (ie, escitalopram, citalopram, venlafaxine, fluvoxamine, fluoxetine, sertraline, paroxetine, and duloxetine)...
2016: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/27820159/using-a-graphical-risk-tool-to-examine-willingness-to-take-migraine-prophylactic-medications
#7
Dana P Turner, Adrienne N Golding, Timothy T Houle
Many migraine sufferers use daily prophylactic therapy to reduce the frequency of their headache attacks. The Food and Drug Administration has approved several different medications for migraine prophylaxis, but it is not clear whether sufferers perceive these treatments to provide clinically significant benefits given their side effect profiles. Three hundred headache sufferers were recruited from the community and local headache clinics using print and television advertising. Participants reported experiencing problematic headache attacks with a median (IQR) frequency of 7...
October 2016: Pain
https://www.readbyqxmd.com/read/27808426/venlafaxine-and-oxycodone-have-different-effects-on-spinal-and-supra-spinal-activity-in-man-a-somatosensory-evoked-potential-study
#8
Dina Lelic, Massimiliano Valeriani, Iben W D Fischer, Albert Dahan, Asbjørn M Drewes
INTRODUCTION: Opioids and antidepressants that inhibit serotonin and norepinephrine reuptake (SNRI) are recognized as analgesics to treat severe and moderate pain, but for both of them the mechanisms in humans remain unclear. This study aimed to explore how oxycodone (opioid) and venlafaxine (SNRI) modulate spinal and supraspinal sensory processing. METHODS: Twenty volunteers were included in this randomized, double blinded, three-way (placebo, oxycodone, venlafaxine), cross-over study...
November 3, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27807990/usefulness-of-repetitive-transcranial-magnetic-stimulation-as-a-maintenance-treatment-in-patients-with-major-depression
#9
Frédéric Haesebaert, Rémi Moirand, Anne-Marie Schott-Pethelaz, Jérôme Brunelin, Emmanuel Poulet
OBJECTIVE: To investigate the clinical efficacy of repetitive Transcranial Magnetic Stimulation (rTMS), venlafaxine or a combination of both treatments as a maintenance treatment in patients with treatment-resistant depression (TRD). METHODS: In a 3-arm open-label study, 66 patients, including 45 remitters, who responded to rTMS (n = 25), venlafaxine (n = 22), or a combination of both treatments (n = 19) continued to receive the treatment that led to a response as a maintenance treatment over 12-month...
November 3, 2016: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/27805299/step-wise-loss-of-antidepressant-effectiveness-with-repeated-antidepressant-trials-in-bipolar-ii-depression
#10
Jay D Amsterdam, Lorenzo Lorenzo-Luaces, Robert J DeRubeis
OBJECTIVE: This study examined the relationship between the number of prior antidepressant treatment trials and step-wise increase in pharmacodynamic tolerance (or progressive loss of effectiveness) in subjects with bipolar II depression. METHODS: Subjects ≥18 years old with bipolar II depression (n=129) were randomized to double-blind venlafaxine or lithium carbonate monotherapy for 12 weeks. Responders (n=59) received continuation monotherapy for six additional months...
November 2016: Bipolar Disorders
https://www.readbyqxmd.com/read/27794623/a-meta-analysis-of-the-efficacy-of-venlafaxine-er-75-to-225%C3%A2-mg-d-for-the-treatment-of-mdd
#11
Michael Thase, Yuko Asami, Dalia Wajsbrot, Kathleen Dorries, Matthieu Boucher, Elizabeth Pappadopulos
OBJECTIVE: To evaluate the short-term efficacy of venlafaxine extended release (ER) 75-225 mg/d compared with placebo for treating major depressive disorder (MDD) and to examine associations between baseline characteristics and efficacy outcomes in MDD patients treated with venlafaxine ER 75-225 mg/d. RESEARCH DESIGN AND METHODS: This meta-analysis included published and unpublished short-term, double-blind, placebo-controlled, Wyeth/Pfizer sponsored studies of venlafaxine ER at doses up to 225 mg/d in adults with MDD...
October 31, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27752949/exposure-to-ssri-type-antidepressants-increases-righting-time-in-the-marine-snail-ilyanassa-obsoleta
#12
Peter P Fong, Taylor B S Bury, Elizabeth E Donovan, Olivia J Lambert, Julia R Palmucci, Stephnie K Adamczak
Exposure to human antidepressants has been shown to disrupt locomotion and other foot-mediated mechanisms in aquatic snails. We tested the effect of three selective serotonin reuptake inhibitor (SSRI)- and one selective serotonin-norepinephrine reuptake inhibitor (SNRI)-type antidepressants on the righting response in the marine snail, Ilyanassa obsoleta. All four antidepressants (fluoxetine, sertraline, paroxetine, venlafaxine) significantly increased righting time compared with controls with an exposure time as short as 1 h...
October 17, 2016: Environmental Science and Pollution Research International
https://www.readbyqxmd.com/read/27751751/venlafaxine-drug-interaction-in-the-diagnosis-of-pheochromocytoma
#13
Ana Belén Mañas-Martínez, Alicia Aragoneses-Calvo, Ana Matei, Sylvie Ojeda-Rodríguez, Pilar García-Durruti
No abstract text is available yet for this article.
December 2016: Endocrinología y Nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición
https://www.readbyqxmd.com/read/27749679/interaction-between-risperidone-venlafaxine-and-metronidazole-an-unknown-thread
#14
Jana Hovancakova, Georgios Schoretsanitis, Michael Grözinger, Gerhard Gründer, Michael Paulzen
No abstract text is available yet for this article.
October 4, 2016: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27748551/venlafaxine-and-oxycodone-effects-on-human-spinal-and-supraspinal-pain-processing-a-randomized-cross-over-trial
#15
D Lelic, I W D Fischer, A E Olesen, C D Mørch, F G Arguissain, J A B Manresa, A Dahan, A M Drewes
Severe pain is often treated with opioids. Antidepressants that inhibit serotonin and norepinephrine reuptake (SNRI) have also shown a pain relieving effect, but for both SNRI and opioids, the specific mode of action in humans remains vague. This study investigated how oxycodone and venlafaxine affect spinal and supraspinal pain processing. Twenty volunteers were included in this randomized cross-over study comparing 5-day treatment with venlafaxine, oxycodone and placebo. As a proxy of the spinal pain transmission, the nociceptive withdrawal reflex (NWR) to electrical stimulation on the sole of the foot was recorded at the tibialis anterior muscle before and after 5 days of treatment...
October 17, 2016: European Journal of Neuroscience
https://www.readbyqxmd.com/read/27747715/coma-after-quetiapine-fumarate-intentional-overdose-in-a-71-year-old-man-a-case-report
#16
S Gibiino, A Trappoli, B Balzarro, A R Atti, D De Ronchi
A 71-year-old man developed coma with severe respiratory failure, hypotension, and tachycardia induced by the intentional ingestion of quetiapine fumarate extended release (XR) 20 g. At the time, he had been treated for bipolar depression with venlafaxine 75 mg/day, lamotrigine 100 mg/day, pregabalin 75 mg/day, and quetiapine XR 400 mg/day for approximately 1 year. Comorbidities were hypertension treated with metoprolol, diabetes mellitus type 2 treated with metformin, and benign prostatic hyperplasia treated with silodosin...
December 2015: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/27738377/an-open-label-pilot-study-of-adjunctive-asenapine-for-the-treatment-of-posttraumatic-stress-disorder
#17
Patricia Pilkinton, Carlos Berry, Seth Norrholm, Al Bartolucci, Badari Birur, Lori L Davis
OBJECTIVE: Selective serotonin reuptake inhibitors (SSRIs) remain the first-line treatment for posttraumatic stress disorder (PTSD). However, adjunctive atypical antipsychotics are often used to target residual or refractory symptoms. Asenapine is a novel atypical antipsychotic that possesses a high serotonin (5-HT2A) to dopamine (D2) affinity ratio and alpha-adrenergic antagonism, which may be advantageous in treating PTSD. This pilot study aimed to identify the therapeutic potential of asenapine as an adjunctive treatment for PTSD...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27722026/venlafaxine-induced-bruising-a-case-report
#18
Jasmine E Carpenter, Juliette Fombi, Otoobong Udoka, Vicenzio Holder-Perkins
No abstract text is available yet for this article.
2016: Primary Care Companion to CNS Disorders
https://www.readbyqxmd.com/read/27716552/venlafaxine-and-takotsubo-syndrome-can-we-learn-more-from-published-patient-cases
#19
John E Madias
No abstract text is available yet for this article.
October 1, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27712567/development-and-optimization-of-controlled-porosity-osmotic-tablets-of-lamotrigine-solid-dispersion
#20
Gayatri C Patel, Megha Kasarwala
BACKGROUND: The purpose of this study was to investigate the application of a controlled porosity osmotic tablet (CPOT) utilizing solid dispersion (SD) of poorly soluble drug. The patents on Cyclobenzaprine HCl (US4968507 A) and Venlafaxine salts (EP 2085078 A1) helped in selection of drug and polymers. METHOD: The SDs having different ratio of drug to carrier (PVP K 30) were prepared by kneading method and optimized. Effect of three independent variables, total amount of osmogen (mannitol& potassium chloride), total amount of polymer (polyethylene oxide WSR 301, hydroxy propyl methyl cellulose K100 M), and polymer1: polymer 2 ratio was investigated using Box Behnken design...
October 4, 2016: Recent Patents on Drug Delivery & Formulation
keyword
keyword
28998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"